The group's principal activities are to discover and develop new drugs for the treatment of neurological, inflammatory, pain and metabolic disorders. Through its accelerated intelligent drug discovery (TM) platform, it discovers compounds that hit new potential drug targets, evaluates the utility of those targets and optimizes useful leads into new drug candidates. The group has collaboration agreements with aventis pharmaceuticals for the discovery and research of crf1 receptor-based drugs. It also has a technology transfer agreement with pfizer inc. For the licensing and transfer of the group's proprietary technologies for the discovery of new drugs to pfizer as well as collaboration agreements for the discovery of gaba-based drugs for anxiety and cognitive disorders.
